AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers

Reference code :: wf382
Published date :: 28 March 2001
Expired date :: 13 August 2028

AstraZeneca today submitted a dossier to the Medicines Control Agency, the UK regulatory authority, for the use of Casodex™ (bicalutamide) 150mg in the treatment of localised and locally advanced prostate cancer - Early Prostate Cancer (EPC). This is the first submission, two years earlier than the planned date, and will be followed by subsequent submissions around the world, with the objective of providing clinicians and patients with an additional treatment option for the early stages of prostate cancer.